{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"60.3","value":"612361"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"title":"Cycle 1 - day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"35","value":"749717"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"Cycle 1 - day 29"}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"Area under concentration (AUC) versus time curve of the AFM13 in serum over time interval from 0 extrapolated to infinity.\n\nGeometric coefficient of variation is given in percentages.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Subjects with Relapsed or Refractory CD30 positive Peripheral T-cell Lymphoma (PTCL).","id":"OG000","title":"Cohort A"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The pharmacokinetic set (PK) consists of subjects who had at least received one dose of study drug and had at least one post dose PK measurement.","reportingStatus":"POSTED","timeFrame":"Predose and 1 hour after start of infusion, end of injection (EOI) and 1 hour, 2 hours, 3 hours, 24 hours and 48 hours after EOI on Cycle 1 Day 1 and Day 29.","title":"Area Under the Concentration-Time Curve of AFM13 From 0 to Infinity (AUC 0-∞)","type":"SECONDARY","unitOfMeasure":"nanogram*hour/milliliter"}